Caribou Biosciences, Inc.
CRBU
$1.84
-$0.07-3.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.16M | 9.30M | 9.12M | 9.92M | 9.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.16M | 9.30M | 9.12M | 9.92M | 9.99M |
| Cost of Revenue | 49.26M | 55.91M | 63.93M | 64.62M | 64.50M |
| Gross Profit | -38.10M | -46.61M | -54.81M | -54.70M | -54.50M |
| SG&A Expenses | 37.91M | 39.82M | 40.47M | 41.55M | 46.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.35M | 155.91M | 164.58M | 173.45M | 176.61M |
| Operating Income | -136.19M | -146.62M | -155.45M | -163.53M | -166.62M |
| Income Before Tax | -148.68M | -157.14M | -164.27M | -147.87M | -149.11M |
| Income Tax Expenses | -550.00K | -9.00K | -9.00K | -9.00K | -9.00K |
| Earnings from Continuing Operations | -148.13 | -157.13 | -164.26 | -147.86 | -149.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -148.13M | -157.13M | -164.26M | -147.86M | -149.11M |
| EBIT | -136.19M | -146.62M | -155.45M | -163.53M | -166.62M |
| EBITDA | -132.55M | -142.47M | -150.76M | -159.15M | -162.69M |
| EPS Basic | -1.59 | -1.70 | -1.79 | -1.62 | -1.65 |
| Normalized Basic EPS | -0.91 | -0.98 | -1.03 | -1.01 | -1.03 |
| EPS Diluted | -1.59 | -1.70 | -1.79 | -1.62 | -1.65 |
| Normalized Diluted EPS | -0.91 | -0.98 | -1.03 | -1.01 | -1.03 |
| Average Basic Shares Outstanding | 373.54M | 370.16M | 367.33M | 364.64M | 361.26M |
| Average Diluted Shares Outstanding | 373.54M | 370.16M | 367.33M | 364.64M | 361.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |